SCHEMBL6494766

SCHEMBL6494766

Nc1ccc2oc3cccc(C(=O)NOC(F)(F)c4c(Cl)cncc4Cl)c3c2c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 2/20 0.34
MAPT P10636 4/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
GFER P55789 1/20 0.32
EGFR P00533 2/20 0.32
IGF1R P08069 2/20 0.32
PDE4B Q07343 3/20 0.32
TTR P02766 1/20 0.32
JAK2 O60674 1/20 0.31
TYK2 P29597 1/20 0.31
TRPV1 Q8NER1 1/20 0.31
GSK3B P49841 1/20 0.31
GAA P10253 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5025239 0.71 NPC1 (0.42) PDE4DNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL5619680 0.71 MAPT (0.39) MAPTNPC1RAB9A
SCHEMBL5022681 0.71 ALDH1A1 (0.40) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL5025403 0.70 NPC1 (0.34) PDE4DNPC1RAB9APDE4BTTR
SCHEMBL5547458 0.70 NPC1 (0.36) PDE4DMAPTNPC1RAB9AMEN1
SCHEMBL5025294 0.69 TLR7 (0.39) MAPTMEN1KMT2APOLB
SCHEMBL4035701 0.69 LMNA (0.37) PDE4DMAPTNPC1RAB9AMEN1
SCHEMBL13632194 0.66 PDE4D (0.51) PDE4DGFERPDE4BJAK2TYK2
SCHEMBL4026556 0.65 PDE4D (0.73) PDE4DPDE4BPDE4APDE4C
SCHEMBL4028281 0.65 PDE4D (0.63) PDE4DGFERPDE4BPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050027129-A1 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them GLENMARK PHARMACEUTICALS, INC. USA 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050027129-A1 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them PDE4A, PDE4B, PDE12 PDE4D 4/4885MAPT 850/4885NPC1 2455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.